Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Conditions

• Dose Escalation
• Safety
• Preliminary Efficacy
• Advanced Solid Tumors
• Metastatic Breast Cancer
• Advanced Pancreatic Adenocarcinoma
• Metastatic Colorectal Cancer
• Recurrent Glioblastoma Multiforme
• Gastric Cancer
• Gastroesophageal Junction Cancer
• Triple Negative Metastatic Breast Cancer
• Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer

Interventions

• DRUG: LDE225
• DRUG: BKM120

Sponsor

Novartis Pharmaceuticals